Navigation Links
CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
Date:6/23/2008

LOS ANGELES, June 23 /PRNewswire-FirstCall/ -- Canopus BioPharma, Inc. (OTC: CBIA), is pleased to announce that the South African Medicines Control Council has granted approval for a Phase II study in 30 cancer patients evaluating the protective effect of CB1400 on the gastrointestional tract from radiation-induced mucositis. This new trial is an important step forward in the development of CB1400 as a novel, preventative, anti-mucositis agent.

Oral and gastrointestinal (GI) mucositis is a painful, debilitating, and sometimes fatal, side-effect of radiation therapy and cancer chemotherapy. No preventative mucositis medicines are available, and few treatments are effective. With some cancer therapies, oral mucositis can develop in over 90% of patients. Consequently, it is a widespread problem with considerable economic and healthcare implications. There is a real need for an effective and well-tolerated mucositis prophylactic. The US market for a preventative mucositis agent is estimated to be over $1 billion per annum.

In work carried out on behalf of Canopus, CB1400 has already been shown to have protective and antimutagenic effects when tested in an animal model of mucositis. Complete protection of the GI tract was seen in gamma-radiated mice pre-treated with oral CB1400 (100 mg/kg/day). Even with high doses of radiation (10Gy), there was no evidence of mucositis: weight gain was observed in the CB1400 pre-treated groups; all mice treated with placebo died.

Canopus BioPharma Inc. has applied to undertake further clinical studies with leading oncologists in Australia, South Africa and the USA, investigating CB1400 as a preventative mucositis agent in head and neck cancer patients who are receiving radiation and/or chemotherapy.

About Canopus BioPharma, Inc.:

Canopus BioPharma, Inc. (OTCBB: CBIA) is dedicated to providing the safest, most cost effective and efficacious pharmaceutical products and assay methods in the areas of infectious disease, radiation protection, cancer, and addiction. With innovative science, proven research and development leadership, and superior products and compounds, Canopus BioPharma has, since 2001, been committed to becoming a market trend setter in a new era of healthcare. In addition, the Company is a world leader in the development of novel camelid antibody products to provide unique avenues of progress and improvement in assay methods and monitoring capabilities for physicians, patients and researchers, particularly for food chain protection applications. Canopus maintains staff in Australia, South Africa, Ireland, Panama and the USA. Additional information on the Company is available at http://www.canopusbiopharma.com.


'/>"/>
SOURCE Canopus BioPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System
2. ArtJen Announces Major Clinical Trial of Its Patented Weight Loss Product FBCx
3. Canopus BioPharma Strengthens its CB1400 Platform Technology for Mucositis and Oncology Treatments Through License Agreement With Wisconsin Alumni Research Foundation
4. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
5. Bavarian Nordic Enters Clinical Trials with HIV Multiantigen Vaccine
6. Ovarian Cancer Vaccine Clinical Trial Begins at Cancer Treatment Centers of America
7. Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting
8. World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research
9. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
10. ESBATechs Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
11. STAR Cranial Centers of Excellence Offer Cutting-Edge Treatment to Dallas Area Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... The key factors driving the growth of dialysis ... growth and increasing healthcare expenditure. Some of the noteworthy trends ... ESRD patients, rising demand for home PD treatment and huge ... market is hindered by high treatment costs and stringent regulations. ... Complete ...
(Date:3/23/2017)... Calif. and INDIANAPOLIS , ... LLY ) and the William Sansum Diabetes ... lives of Latino people affected by diabetes through enhanced ... burden of diabetes and cardiovascular disease bears a disproportionate ... States ," said David Kerr , M.D., ...
(Date:3/23/2017)... March 23, 2017   BioSpace , the leading ... partnered with Indiana Biosciences Research Institute and ... and educational institutions to bring the state,s life sciences ... Hotbed map, an artistic representation of the region,s booming ... to Vice President Mike Pence , a long-time ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... ... military at the same time by providing Prehospital Trauma Life Support (PHTLS) course ... the world’s premier prehospital trauma education developed in cooperation with the American College ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... world countries to hospitals in the United States, it’s a threat that is ... current obstacles facing infection prevention and offers strategies for the healthcare community to ...
(Date:3/24/2017)... ... March 24, 2017 , ... The Radiology Business Management Association ... The annual awards, now in their 12th year, are among the most prestigious in ... In 2016, the awards were retooled to recognize achievements in both large budget (over ...
(Date:3/24/2017)... ... March 24, 2017 , ... Texas Physical Therapy Specialists (TexPTS) ... found at 9618 Huebner Road. The clinic is the group’s 7th location in San ... Dr. Ali Higgins, PT, will provide care from the clinic, which opened March 22, ...
(Date:3/24/2017)... Orion, MI (PRWEB) , ... March 24, 2017 ... ... insurance assistance, financial planning, and related services to families and business owners across ... initiative aimed at feeding regional families struggling with financial difficulties. , The Oxford/Orion ...
Breaking Medicine News(10 mins):